Bicara Therapeutics Inc.
BCAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Bicara Therapeutics Inc. (BCAX) is listed under Biotechnology. Valued at $1.82B, BCAX is a small-cap name in its sector. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Market Cap
$1.82B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.64
EPS (TTM)
$-2.79
EPS (Fwd)
$-3.63
ROE
-32.3%
ROA
-21.1%
Cash
$539.8M
Total Debt
$1.4M
Free CF
-$68.4M
52W Change
154.0%
Annual Financials
Cash vs Debt
With $539.8M in cash and $1.4M in debt, BCAX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$68.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -32.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BCAX.